Inhibition of the PI3K/AKT Pathway Potentiates Cytotoxicity of EGFR Kinase Inhibitors in Triple-negative Breast Cancer Cells

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2013 Apr 23

PMID 23601074

Citations 51

Authors

Yong Weon Yi

Wooyoung Hong

Hyo Jin Kang

Hee Jeong Kim

Wenjing Zhao

Antai Wang

Yeon-Sun Seong

Insoo Bae

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancers (TNBCs) are known to be intrinsically resistant to inhibitors for epidermal growth factor receptor (EGFR). Until now, clinical trials for TNBCs using EGFR inhibitors (EGFRis) as single agents have yielded disappointing results. Here, we report that combinatorial treatment using EGFRis, such as gefitinib or erlotinib, with PI3K/AKT pathway inhibitors (PI3K/AKTis) demonstrated a synergistic, anti-proliferative effect in cell lines of the basal-like (BL) subtype, a subtype of TNBC. Western blot analysis revealed that the gefitinib/PI-103 combination significantly reduced the level of both phospho-AKT and phospho-ERK in two susceptible BL subtype cell lines, SUM149PT and MDA-MB-468, whereas it had little or no effect on the level of phospho-ERK in two non-susceptible cell lines (HS578T and MDA-MB-231) of mesenchymal stem-like (MSL) TNBC subtype. The gefitinib/PI-103 combination also significantly induced caspase-3/7-mediated PARP cleavage and reduced two anti-apoptotic proteins, XIAP and Bcl-2 in the susceptible cell lines. In addition, the level of myeloid cell leukemia 1 (Mcl-1) protein was markedly decreased by gefitinib/PI-103 combination in the BL TNBC cells, but showed no significant change by this combination in MSL subtype cells. These results suggest that pharmacological inhibition of EGFR used in combination of PI3K/AKTis is a potential therapeutic approach to treat a subtype of TNBCs.

Citing Articles

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.

Khan Y, Rizvi S, Raza A, Khan A, Hussain S, Khan N Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40029385 DOI: 10.1007/s00210-025-03896-4.

EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma.

Hu L, Shi W, Liu K, Ma D, Xin Q, Wang Z Front Med (Lausanne). 2024; 11:1464610.

PMID: 39606630 PMC: 11598357. DOI: 10.3389/fmed.2024.1464610.

Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells.

Kar T, Dugam P, Shivhare S, Shetty S, Choudhury S, Sen D Cancer Rep (Hoboken). 2024; 7(3):e2049.

PMID: 38522013 PMC: 10961089. DOI: 10.1002/cnr2.2049.

Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer.

Jaradat S, Ayoub N, Al Sharie A, Aldaod J Technol Cancer Res Treat. 2024; 23:15330338241234780.

PMID: 38389413 PMC: 10894558. DOI: 10.1177/15330338241234780.

Small molecule agents for triple negative breast cancer: Current status and future prospects.

Ou Y, Wang M, Xu Q, Sun B, Jia Y Transl Oncol. 2024; 41:101893.

PMID: 38290250 PMC: 10840364. DOI: 10.1016/j.tranon.2024.101893.

References

Mueller K, Madden J, Zoratti G, Kuperwasser C, List K, Boerner J . Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res. 2012; 14(4):R104. PMC: 3680928. DOI: 10.1186/bcr3224. View

Dillon R, Muller W . Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 2010; 70(11):4260-4. PMC: 2880222. DOI: 10.1158/0008-5472.CAN-10-0266. View

Schwickart M, Huang X, Lill J, Liu J, Ferrando R, French D . Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2009; 463(7277):103-7. DOI: 10.1038/nature08646. View

Hafsi S, Pezzino F, Candido S, Ligresti G, Spandidos D, Soua Z . Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol. 2011; 40(3):639-44. DOI: 10.3892/ijo.2011.1312. View

Chipuk J, Moldoveanu T, Llambi F, Parsons M, Green D . The BCL-2 family reunion. Mol Cell. 2010; 37(3):299-310. PMC: 3222298. DOI: 10.1016/j.molcel.2010.01.025. View

Wong T, Lee F, Yu C, Luo F, Oppenheimer S, Zhang H . Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006; 12(20 Pt 1):6186-93. DOI: 10.1158/1078-0432.CCR-06-0642. View

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B . Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res. 2010; 70(21):8852-62. DOI: 10.1158/0008-5472.CAN-10-1039. View

Aird K, Ghanayem R, Peplinski S, Lyerly H, Devi G . X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther. 2010; 9(5):1432-42. PMC: 2957814. DOI: 10.1158/1535-7163.MCT-10-0160. View

Yi Y, Kang H, Kim H, Hwang J, Wang A, Bae I . Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Mol Carcinog. 2012; 52(9):667-75. PMC: 3586771. DOI: 10.1002/mc.21905. View

10.

Mills J, Hippo Y, Robert F, Chen S, Malina A, Lin C . mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A. 2008; 105(31):10853-8. PMC: 2504845. DOI: 10.1073/pnas.0804821105. View

11.

Eccles S . The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011; 55(7-9):685-96. DOI: 10.1387/ijdb.113396se. View

12.

Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K . MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010; 9(7):1956-67. DOI: 10.1158/1535-7163.MCT-09-1012. View

13.

Jones L, Sampson A, Kang H, Kim H, Yi Y, Kwon S . Loss of BRCA1 leads to an increased sensitivity to Bisphenol A. Toxicol Lett. 2010; 199(3):261-8. PMC: 3505996. DOI: 10.1016/j.toxlet.2010.09.008. View

14.

Srivastava A, Pandey S . Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem. 1998; 182(1-2):135-41. View

15.

Maurer U, Charvet C, Wagman A, Dejardin E, Green D . Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006; 21(6):749-60. DOI: 10.1016/j.molcel.2006.02.009. View

16.

Normanno N, Morabito A, De Luca A, Piccirillo M, Gallo M, Maiello M . Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer. 2009; 16(3):675-702. DOI: 10.1677/ERC-08-0208. View

17.

Carey L, Winer E, Viale G, Cameron D, Gianni L . Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol. 2010; 7(12):683-92. DOI: 10.1038/nrclinonc.2010.154. View

18.

Knight Z, Gonzalez B, Feldman M, Zunder E, Goldenberg D, Williams O . A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006; 125(4):733-47. PMC: 2946820. DOI: 10.1016/j.cell.2006.03.035. View

19.

Burness M, Grushko T, Olopade O . Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer J. 2010; 16(1):23-32. DOI: 10.1097/PPO.0b013e3181d24fc1. View

20.

Metzger-Filho O, Tutt A, de Azambuja E, Saini K, Viale G, Loi S . Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012; 30(15):1879-87. DOI: 10.1200/JCO.2011.38.2010. View